Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156409369> ?p ?o ?g. }
- W2156409369 endingPage "3422" @default.
- W2156409369 startingPage "3416" @default.
- W2156409369 abstract "Purpose Given that the clinical course of oxaliplatin-induced neuropathy is not well defined, the current study was performed to better understand clinical parameters associated with its presentation. Methods Acute and chronic neuropathy was evaluated in patients receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08CB (North Central Cancer Treatment Group, Alliance). Acute neuropathy was assessed by having patients complete daily questionnaires for 6 days with each cycle of FOLFOX. Before each dose of FOLFOX and as long as 18 months after chemotherapy cessation, chronic neurotoxicity was assessed with use of the 20-item, European Organisation for Research and Treatment of Cancer quality-of-life questionnaire for patients with chemotherapy-induced peripheral neuropathy. Results Three hundred eight (89%) of the 346 patients had at least one symptom of acute neuropathy with the first cycle of FOLFOX; these symptoms included sensitivity to touching cold items (71%), sensitivity to swallowing cold items (71%), throat discomfort (63%), or muscle cramps (42%). Acute symptoms peaked at day 3 and improved, although they did not always resolve completely between treatments. These symptoms were about twice as severe in cycles 2 through 12 as they were in cycle 1. For chronic neurotoxicity, tingling was the most severe symptom, followed by numbness and then pain. During chemotherapy, symptoms in the hands were more prominent than they were in the feet; by 18 months, symptoms were more severe in the feet than they were in the hands. Patients with more severe acute neuropathy during the first cycle of therapy experienced more chronic sensory neurotoxicity (P < .0001). Conclusion Acute oxaliplatin-induced neuropathy symptoms do not always completely resolve between treatment cycles and are only half as severe on the first cycle as compared with subsequent cycles. There is a correlation between the severities of acute and chronic neuropathies." @default.
- W2156409369 created "2016-06-24" @default.
- W2156409369 creator A5008767553 @default.
- W2156409369 creator A5015361329 @default.
- W2156409369 creator A5027044033 @default.
- W2156409369 creator A5027306320 @default.
- W2156409369 creator A5031116230 @default.
- W2156409369 creator A5035951749 @default.
- W2156409369 creator A5045054591 @default.
- W2156409369 creator A5055078584 @default.
- W2156409369 creator A5057458005 @default.
- W2156409369 creator A5064449830 @default.
- W2156409369 creator A5075414543 @default.
- W2156409369 creator A5081499786 @default.
- W2156409369 creator A5084777911 @default.
- W2156409369 date "2015-10-20" @default.
- W2156409369 modified "2023-10-16" @default.
- W2156409369 title "Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)" @default.
- W2156409369 cites W1519813906 @default.
- W2156409369 cites W1522874901 @default.
- W2156409369 cites W1819542632 @default.
- W2156409369 cites W1966585853 @default.
- W2156409369 cites W1971192992 @default.
- W2156409369 cites W1984518802 @default.
- W2156409369 cites W1999935086 @default.
- W2156409369 cites W2018524062 @default.
- W2156409369 cites W2035889265 @default.
- W2156409369 cites W2042038698 @default.
- W2156409369 cites W2056787838 @default.
- W2156409369 cites W2058983865 @default.
- W2156409369 cites W2059074940 @default.
- W2156409369 cites W2061842312 @default.
- W2156409369 cites W2071957083 @default.
- W2156409369 cites W2080382070 @default.
- W2156409369 cites W2086134694 @default.
- W2156409369 cites W2096610541 @default.
- W2156409369 cites W2102583849 @default.
- W2156409369 cites W2104359049 @default.
- W2156409369 cites W2120713475 @default.
- W2156409369 cites W2142831070 @default.
- W2156409369 cites W2147145155 @default.
- W2156409369 cites W2148454282 @default.
- W2156409369 cites W2153407324 @default.
- W2156409369 cites W2158499547 @default.
- W2156409369 cites W2163024772 @default.
- W2156409369 cites W143592514 @default.
- W2156409369 doi "https://doi.org/10.1200/jco.2014.58.8533" @default.
- W2156409369 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4606060" @default.
- W2156409369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26282635" @default.
- W2156409369 hasPublicationYear "2015" @default.
- W2156409369 type Work @default.
- W2156409369 sameAs 2156409369 @default.
- W2156409369 citedByCount "206" @default.
- W2156409369 countsByYear W21564093692015 @default.
- W2156409369 countsByYear W21564093692016 @default.
- W2156409369 countsByYear W21564093692017 @default.
- W2156409369 countsByYear W21564093692018 @default.
- W2156409369 countsByYear W21564093692019 @default.
- W2156409369 countsByYear W21564093692020 @default.
- W2156409369 countsByYear W21564093692021 @default.
- W2156409369 countsByYear W21564093692022 @default.
- W2156409369 countsByYear W21564093692023 @default.
- W2156409369 crossrefType "journal-article" @default.
- W2156409369 hasAuthorship W2156409369A5008767553 @default.
- W2156409369 hasAuthorship W2156409369A5015361329 @default.
- W2156409369 hasAuthorship W2156409369A5027044033 @default.
- W2156409369 hasAuthorship W2156409369A5027306320 @default.
- W2156409369 hasAuthorship W2156409369A5031116230 @default.
- W2156409369 hasAuthorship W2156409369A5035951749 @default.
- W2156409369 hasAuthorship W2156409369A5045054591 @default.
- W2156409369 hasAuthorship W2156409369A5055078584 @default.
- W2156409369 hasAuthorship W2156409369A5057458005 @default.
- W2156409369 hasAuthorship W2156409369A5064449830 @default.
- W2156409369 hasAuthorship W2156409369A5075414543 @default.
- W2156409369 hasAuthorship W2156409369A5081499786 @default.
- W2156409369 hasAuthorship W2156409369A5084777911 @default.
- W2156409369 hasBestOaLocation W21564093692 @default.
- W2156409369 hasConcept C121608353 @default.
- W2156409369 hasConcept C126322002 @default.
- W2156409369 hasConcept C134018914 @default.
- W2156409369 hasConcept C141071460 @default.
- W2156409369 hasConcept C2776694085 @default.
- W2156409369 hasConcept C2778260052 @default.
- W2156409369 hasConcept C2778616394 @default.
- W2156409369 hasConcept C2779289229 @default.
- W2156409369 hasConcept C2779819292 @default.
- W2156409369 hasConcept C2779901536 @default.
- W2156409369 hasConcept C2780962732 @default.
- W2156409369 hasConcept C526805850 @default.
- W2156409369 hasConcept C555293320 @default.
- W2156409369 hasConcept C71924100 @default.
- W2156409369 hasConceptScore W2156409369C121608353 @default.
- W2156409369 hasConceptScore W2156409369C126322002 @default.
- W2156409369 hasConceptScore W2156409369C134018914 @default.
- W2156409369 hasConceptScore W2156409369C141071460 @default.
- W2156409369 hasConceptScore W2156409369C2776694085 @default.
- W2156409369 hasConceptScore W2156409369C2778260052 @default.
- W2156409369 hasConceptScore W2156409369C2778616394 @default.